Who are CAPOX 3 month's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Anlotinib plus Pemetrexed, 5-fluoro-uracil, oxaliplatin plus capecitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capox-3-month.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CAPOX 3 month — Competitive Intelligence Brief

CAPOX 3 month (CAPOX 3 month) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite. Area: Oncology.

phase 2 Antimetabolite Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CAPOX 3 month (CAPOX 3 month) — NRG Oncology. Capecitabine is a thymidylate synthase inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CAPOX 3 month TARGET	CAPOX 3 month	NRG Oncology	phase 2	Antimetabolite	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Anlotinib plus Pemetrexed	Anlotinib plus Pemetrexed	Henan Provincial People's Hospital	marketed	Multi-target tyrosine kinase inhibitor plus antifolate antimetabolite	VEGFR, FGFR, RET, c-Kit (anlotinib); thymidylate synthase, DHFR, GARFT (pemetrexed)
5-fluoro-uracil	5-fluoro-uracil	UNICANCER	marketed	Antimetabolite	Thymidylate synthase; RNA and DNA incorporation
oxaliplatin plus capecitabine	oxaliplatin plus capecitabine	LiNing	marketed	Platinum-based chemotherapy combination	DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite class)

Grupo Espanol Multidisciplinario del Cancer Digestivo · 2 drugs in this class
NRG Oncology · 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Centre Oscar Lambret · 1 drug in this class
Iwate Medical University · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CAPOX 3 month — Competitive Intelligence Brief. https://druglandscape.com/ci/capox-3-month. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab